Updates

Cineworld

September 2019

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

As previously flagged, the first half results from Cineworld saw a decline in sales and EBITDA of 11% and 11.8%, respectively, to US$2,152m and US$488.5m. Eps was 14.7 cents while net debt / EBITDA was 3.3x.The figures reflect a weak film slate, with the major film releases expected in the second half. Management highlights potential blockbusters in H2 including Spider Man, Far From Home; The Lion King; Fast and Furious presents Hobbs & Shaw; It: Chapter Two; Joker; Terminator: Dark Fate; Frozen 2 and Star Wars, The Rise of Skywalker.Broker Jefferies says July and August were strong, while the unlimited monthly subscription product was launched within the Regal business in the USA in August, which should close the gap wit ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

Medica Group

Bovis Homes

Cineworld - Exciting film slate and pent up demand could drive re-rating (September 2021)

Cineworld (April 2020)

Cineworld (February 2020)

Cineworld - Sale and leaseback yields special dividend (July 2019)

Cineworld - Results trigger broker upgrades (May 2019)

Cineworld - Cinema chain transformed by US acquisition (April 2019)

Cineworld (July 2018)

Cineworld - Transformational US acquisition (March 2018)

Cineworld - Cinema operator boosted by Hollywood blockbuster (October 2017)

Cineworld (July 2017)

Cineworld - Acquires five cinemas for Â£94m (October 2016)

Cineworld (May 2016)

Cineworld (March 2016)

Cineworld (October 2015)

Cineworld - Cinema chain to benefit from strong film release schedule (September 2015)

Cineworld - Second largest cinema chain expanding rapidly (July 2015)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X